Rulonilimab
Monoclonal antibody
Rulonilimab is one of 42 small molecule programs targeting Cervical Cancer. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
380 competitors in Cervical Cancer
#DrugCompanyPhaseTrials
1Emend IV
Merck & Co.Phase 3
Hycamtin
MMeitheal
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Gemzar
Eli LillyPhase 3
Rescue
Merck & Co.Phase 3
Vindesine
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
HLX10
Shanghai Henlius BiotechPhase 3
Neoadjuvant Therapy
SSun Yat-sen University
Phase 3
SG001
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cervical Cancer1 trial
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Enrolling by invitation·SShandong New Time Pharmaceutical Co., LTD·Phase 2/3·NCT06755515·510 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rulonilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]